Status:
COMPLETED
Taxotere + Cisplatin in Nasopharyngeal Carcinoma
Lead Sponsor:
Sanofi
Conditions:
Nasopharyngeal Neoplasms
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Primary objective: To assess and compare the toxicities of patients with advanced NPC treated with concurrent cisplatin-radiotherapy with or without neoadjuvant Taxotere (docetaxel) and cisplatin. S...
Eligibility Criteria
Inclusion
- International Union against Cancer stages III and IV newly diagnosed NPC
Exclusion
- Inadequate bone marrow reserve
- Inadequate renal function
- Other primary malignancy
- Evidence of distant metastases
- The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Key Trial Info
Start Date :
December 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2010
Estimated Enrollment :
61 Patients enrolled
Trial Details
Trial ID
NCT00436293
Start Date
December 1 2002
End Date
March 1 2010
Last Update
November 17 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sanofi-Aventis
Hong Kong, Hong Kong